ResMed Inc. (RMD)

NYSE: RMD · USD

—

Dự phòng tiếng AnhVI

Hiển thị bản gốc tiếng Anh trong khi đang dịch

Báo cáo này chưa được dịch. Hãy làm mới sau vài phút khi hàng đợi dịch xử lý xong.

StockMarketAgent Research · Analyzed 2026-10-04

Our latest published analysis: RMD rated Hold

ResMed Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$239 / share

Potential value

$282 / share

Upside to FV

+9.4%

Moat

9/10

Wide

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$30.8B
P/E (forward)	18.5x

Market data

Price

Recent price action with selectable time range.

Financial snapshot

P/E (forward): 18.5x
Market cap: $30.8B

Item	P1	P2	P3	P4	P5	Trend
Period	2022-06-30	2023-06-30	2024-06-30	2025-06-30	2026-06-30	Trend
Revenue	$3.58B	$4.22B	$4.69B	$5.15B	$5.65B	+12.1%
Gross profit	$2.02B	$2.36B	$2.66B	$3.05B	$3.45B	+14.3%
Operating income	$1.00B	$1.13B	$1.32B	$1.69B	$1.89B	+17.2%
Net income	$779.4M	$897.6M	$1.02B	$1.40B	$1.52B	+18.2%
EPS (diluted)	$5.30	$6.09	$6.92	$9.51	$10.43	+18.4%
EBITDA	$1.18B	$1.36B	$1.53B	$1.91B	$2.15B	+16.2%
R&D	$253.6M	$287.6M	$307.5M	$331.3M	$378.3M	+10.5%
SG&A	$737.5M	$874.0M	$917.1M	$993.1M	$1.12B	+11.0%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	—	—	—	—	—	—	Bán
ABNB	Airbnb, Inc.	—	—	—	—	—	—	Bán
ADBE	Adobe Inc.	—	—	—	—	—	—	Mua mạnh
ABBV	AbbVie Inc.	—	—	—	—	—	—	Bán
ABT	Abbott Laboratories	—	—	—	—	—	—	Giảm
ALGN	Align Technology Inc.	—	—	—	—	—	—	Giảm

Base and Bull scenarios

Base60%

Price target

$239.41

+9.4% from spot

Under the base case, ResMed achieves a target valuation of $239.41, representing a return of 9.4% relative to $218.89 with an assigned probability of 60.0%. This scenario requires steady volume growth across cloud-connected sleep therapy devices, sustained high-margin mask replenishment cycles, and manufacturing productivity that counters persistent electronic component inflation. Disconfirmation would occur if core device placements stall or if gross margin fails to recover across upcoming quarters.

Core sleep flow generator and mask resupply demand compounds at steady single-digit rates across major geographic markets.
Manufacturing productivity improvements and modest price adjustments stabilize gross margin against component cost inflation.
Execution of planned share repurchases and regular dividend distributions supports steady per-share earnings expansion.

Bull20%

Price target

$282.29

+29.0% from spot

In the bull case, ResMed reaches Potential value of $282.29, yielding an attractive return of 29.0% against $218.89 with a probability of 20.0%. This upside path requires accelerated patient diagnosis across international markets, rapid resolution of component allocation bottlenecks, and substantial operating leverage from SaaS software platforms following portfolio streamlining. Investors would observe confirmation through accelerating constant-currency revenue growth and expanding operating margins across quarterly reporting checkpoints.

Accelerating sleep apnea diagnosis rates and international market penetration drive double-digit device and mask revenue expansion.
Supply chain component headwinds abate rapidly, driving gross margin expansion well ahead of initial expectations.
Accelerated share repurchases combined with operating leverage deliver superior per-share earnings growth.

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($239.41). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.5%	2.8%	3.0%	3.3%	3.5%
7.6%	$262	$269	$278	$287	$298
8.1%	$244	$250	$257	$264	$272
8.6%	$229	$234	$239	$245	$252
9.1%	$216	$220	$225	$230	$235
9.6%	$205	$209	$212	$216	$221

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Forward P/E18.5

P25 n/aP50 n/aP75 n/a

Trailing P/E21

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

Deeper analysis on RMD

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this RMD report

What is the latest published RMD stock rating?

ResMed Inc. is shown with Hold in the latest published report, analyzed 2026-10-04. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full RMD analysis?

The full latest published report, analyzed 2026-10-04, lives at /stocks/RMD/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for RMD?

The latest published report analyzed 2026-10-04 gives RMD a fair value of USD 239 and a potential value of USD 282. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the RMD page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-04). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

HoldRMD · Fair value $239+9.4%

Read full analysis →

ResMed Inc. (RMD)

Our latest published analysis: RMD rated Hold

Price

Financial snapshot

Fair-value bridge

Latest news · RMD

Valuation

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

Deeper analysis on RMD

Frequently asked questions

Lịch sử xếp hạng

Category	Score	Reading
Valuation	6.0
Management	8.5
Balance Sheet	8.5
Profitability	7.5
Revenue Growth	6.0
Risk Assessment	9.0
Competitive Moat	9.0
Earnings Quality	6.0
Capital Efficiency	7.5